ReShape Lifesciences (RSLS), a prominent medical device company, reported on its second quarter financials for 2024, highlighting a significant reduction in operating expenses and outlining the strategic merger with Vyome Therapeutics.
CEO Paul Hickey and CFO Tom Stankovich provided insights into the company's financial health, including a 45% decrease in operating expenses and a rise in gross profit margin despite lower revenue.
The merger, resulting in the formation of Vyome Holdings, aims to capitalize on the burgeoning healthcare market in India and the company's focus on immuno-inflammatory diseases.
Krishna Gupta, set to become Chairman of Vyome Holdings, discussed the strategic vision, emphasizing the potential for growth and value creation in both the Indian and US markets.
The company, pausing clinical trials to conserve cash, reported an adjusted EBITDA loss reduction and remains debt-free with $2.9 million in net working capital.
Key Takeaways
- ReShape Lifesciences achieved a 45% reduction in operating expenses year-over-year.
- The company is preparing for the commercial launch of LAP-Band 2.0 Flex (NASDAQ:FLEX).
- Vyome Holdings, the new entity post-merger, will focus on immuno-inflammatory diseases.
- ReShape Lifesciences reported a decrease in revenue but an increase in gross profit margin.
- The company has reduced sales and marketing, general and administrative, and R&D expenses.
- Krishna Gupta of Vyome Therapeutics will become Chairman of Vyome Holdings.
- The company has paused clinical trials to preserve cash.
- ReShape Lifesciences reported a non-GAAP adjusted EBITDA loss of $1.9 million for Q2 2024.
- Net working capital stood at $2.9 million at the end of the quarter.
- The company has commitments for additional capital and plans to self-fund into the second half of 2025.
Company Outlook
- Vyome Holdings to focus on treating immuno-inflammatory diseases with innovative solutions.
- Plans to leverage the Indian innovation corridor and the U.S. market for growth.
- The combined company will have no debt and a clean capital structure.
Bearish Highlights
- Reduction in revenue due to decreased sales volume.
- Clinical trial work has been paused to conserve financial resources.
Bullish Highlights
- Increase in gross profit margin and reduction in various operational expenses.
- The company is optimistic about its merger with Vyome Therapeutics.
- Anticipated adequate liquidity to self-fund into the second half of 2025.
Misses
- Non-GAAP adjusted EBITDA loss of $1.9 million for Q2 2024, although improved from last year.
Q&A Highlights
- Discussion on the large market opportunities in India and the success of the Indian IT sector.
- Plans for additional opportunities, partnerships, and acquisitions under Vyome Holdings.
- Commitments for additional capital, including a private placement of $7.3 million.
ReShape Lifesciences has taken significant steps to streamline its operations and prepare for future growth through strategic mergers and asset sales.
With a clear focus on reducing costs and capitalizing on the potential in the healthcare market, the company aims to build on its strengths in the medical device sector while expanding its reach into the treatment of immuno-inflammatory diseases.
The merger with Vyome Therapeutics is set to position the new entity, Vyome Holdings, for success in the global markets, with a strong emphasis on creating value for shareholders and patients alike.
InvestingPro Insights
ReShape Lifesciences (RSLS) has been navigating a challenging financial landscape, as reflected in their recent quarterly report. Key metrics from InvestingPro show a market capitalization of $5.18 million, indicating a relatively small player in the medical device industry. This is coupled with a negative price-to-earnings (P/E) ratio of -0.33, and an even lower adjusted P/E ratio for the last twelve months as of Q2 2024, standing at -0.59, which suggests that investors are concerned about the company's profitability prospects.
Despite these challenges, the company holds more cash than debt on its balance sheet, which can be a positive sign for financial stability and future investments. This is an important aspect as the company aims to self-fund into the second half of 2025 and may provide some reassurance to investors about its ability to navigate short-term obligations.
On the downside, analysts do not anticipate the company will be profitable this year, as reflected in the significant adjusted EBITDA loss reported for Q2 2024. This aligns with the broader trend of the stock's performance, which has fared poorly over the last month, with a 24.78% decline in price total return. This trend extends over a longer period, with an 85.33% drop over the past year.
For investors looking for dividend income, it's noteworthy that ReShape Lifesciences does not pay a dividend to shareholders, which may influence investment decisions for those seeking regular income streams from their holdings.
InvestingPro offers a wealth of additional insights, with 10 more InvestingPro Tips available for those interested in a deeper dive into ReShape Lifesciences' financials and market performance. These tips can be found at https://www.investing.com/pro/RSLS, providing valuable information for investors considering this stock.
Full transcript - ReShape Lifesciences Inc (NASDAQ:RSLS) Q2 2024:
Operator: Good day, and thank you for standing by. Welcome to the ReShape Lifesciences Second Quarter 2024 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Michael Miller, Rx Communications. Please go ahead.
Michael Miller: Good afternoon, and thank you for joining the second quarter 2024 ReShape Life Sciences earnings call. I'm pleased to be joined today by Paul Hickey, President and Chief Executive Officer; and Tom Stankovich, Chief Financial Officer. Management will also be joined by Krishna Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon the completion of the previously announced merger agreement between the two companies. As we do each quarter, Paul will provide an overview and update on the company's activities, and Tom will review the financial results for the period, after which Paul will introduce Krishna for his remarks. As a reminder, this conference call as well as ReShape Lifesciences' SEC filings and website, including the Investor Information section of the website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as Risk Factors in the company's most recent annual report on Form 10-K. As an additional reminder, ReShape stock is listed on NASDAQ, trading under the ticker symbol RSLS. I'll now turn the call over to Paul Hickey, President and CEO of ReShape Lifesciences. Paul?
Paul Hickey: Thank you, Mike, and thanks to all of you for joining us this afternoon for our earnings call for the second quarter of 2024. As Mike noted, after I provide an overview and update on ReShape's activities and Tom reviews the financial performance, Krishna Gupta will take a few moments to share some background and outline the strategy and vision of the NewCo to be called Vyome Holdings, following the closing of our announced merger agreement. Let's begin with an overview of our activities during the second quarter and subsequent period. We've remained laser-focused on stabilizing revenues and maintaining our disciplined approach to continually leveraging resources in order to execute on our 2024 cost reduction plan, which has led to approximately 45% lower operating expenses for the first half of the year compared to last year. As a result, we have stabilized our gross profit margin even with lower sales resulting from the widespread adoption of GLP-1s. Tom will detail these cost reductions later in this call. In addition to these reductions, we continue to fine tune our lead-generation activities and invest in our growth drivers, including the commercial launch of our physician-led redesigned LAP-Band 2.0 Flex. We are currently in the last phase of our limited market release and gathering data and metrics that will be used to support an anticipated widespread commercial launch. Most notably, in July, we coordinated both the merger agreement with Vyome Therapeutics and the concurrent asset purchase agreement with Biorad as well as successfully negotiated with our Series C shareholders to substantially lower their liquidation preference. All things considered, we feel we are successfully maximizing stockholder value and earnings potential. I will detail the transaction a little bit later in this call. Before I do that, I'd like to touch on the obesity market. Obesity is a complex, lifelong disease that requires individualized treatment strategies to achieve sustainable weight loss. GLP-1 receptor agonists have provided considerable advantages for individuals with type 2 diabetes and has also benefited individuals dealing with obesity. However, real-world, long-term tolerability for GLP-1s is low. And based on this evidence, we believe that the market opportunity for the LAP-Band will increase over time, especially with the newly launched next-generation LAP-Band 2.0 FLEX. As most of you are aware, the stigma around obesity and medical intervention has been normalized by the adoption of GLP-1 receptor agonist usage. And we continue to believe that the number of people seeking the help of medical professionals, especially bariatric surgeons over time will increase. In the interim, our cost reductions have allowed us to focus on and optimize the commercialization of our LAP-Band 2.0 FLEX, which was created to improve the patient experience while continuing to market our current LAP-Band. The limited market release of the LAP-Band 2.0 FLEX is nearing completion and is going exceptionally well, and initial surgeon feedback has been very positive. Added to this, our patient friendly website is receiving meaningful traffic, while our co-op marketing program has proven effective and scalable with key LAP-Band centers. As it relates to the recent merger agreement, as most of you know, beginning in December of last year, we conducted a high-priority search for synergistic merger and acquisition opportunities having engaged Maxim (NASDAQ:MXIM) Group LLC on an exclusive basis to assist in this process. To that end, following an extensive evaluation of multiple strategic options and engaging discussions with a number of other potential merger and acquisition candidates, our Board of Directors unanimously recommended the merger with Vyome along with the concurrent asset sale to Biorad. We believe this presents a significant opportunity for our shareholders to capitalize on the potential of the newly formed entity post-merger. As previously reported, Biorad has an exclusive license for our Obalon Gastric Balloon System. We believe they are the most synergistic partner to sell our assets to, including our LAP-Band system, Obalon Gastric Balloon System and the Diabetes Bloc-Stim Neuromodulation system. This asset purchase agreement for $5.16 million in cash will allow us to pay down the costs associated with the Vyome transaction. Notably, our disciplined cost reduction plan facilitated the value we are able to bring to our shareholders. Additionally, I would like to express our gratitude to our Series C preferred stockholders for their willingness to substantially lower their liquidation preference, thereby enabling our common stockholders to recognize the potential value of the merger. Krishna will detail more information on the Vyome transaction later on this call. I'm very excited about the shareholder value and growth potential resulting from these transactions. I'd now like to turn the call over to Tom Stankovich to provide a recap of our financial performance. Tom?
Thomas Stankovich: Thanks, Paul. And once again, thank you all for joining our webcast this afternoon. As Paul mentioned earlier, in response to the short-term impact and adoption of GLP-1s, we have reorganized the company and maintained our disciplined approach on executing our cost reduction plan for 2024. With various cost reductions, we have achieved a 45% reduction in overall operating costs for the first six months of 2024 compared to the same period last year. All expense line items within our operating expenses are lower than the comparable period in the prior year. Additionally, we have stabilized and increased our gross profit margins even with the lower sales due to the adoption of GLP-1s. A full discussion of our financials is available in our press release and 10-Q. I will just take a few moments to review key financial metrics for the second quarter and six months ended June 30, 2024. Our revenue totaled $2 million for the three months ended June 30, 2024, which represents a reduction of $300,000 compared to the same period in 2023. Revenue totaled $3.9 million for the six months ended June 30, 2024, and represents a reduction of $600,000 compared to the same period in 2023. The reason is due to a decrease in sales volume, which is primarily due to GLP-1 pharmaceuticals. Gross profit for the three months ended June 30, 2024, was $1.1 million and was slightly below $1.2 million for the same period in 2023. The gross profit as a percentage of total revenue for the three months ended June 30, 2024, increased to 58% compared to 53% for the same period in 2023. Gross profit for the six months ended June 30, 2024, and 2023 was $2.3 million and $2.4 million, respectively. Gross profit as a percentage of total revenue for the six months ended June 30, 2024, increased to 59% compared to 53% for the same period in 2023. The increase in gross margin, gross profit percentage is due to the reduction in overhead related costs, primarily payroll as the company had a reduction in employees late in 2023. Sales and marketing expenses for the three months ended June 30, 2024, decreased by $1.5 million to $700,000 compared to $2.2 million for the same period in 2023. Sales and marketing expenses for the six months ended June 30, 2024 decreased by $2.7 million or $1.7 million compared to $4.4 million for the same period in 2023. The decreases in the 3- and 6-month periods ended were primarily attributable to a decrease in advertising and marketing spending, including consulting and professional marketing services as the company reevaluated its marketing approach and has moved to a targeted digital marketing campaign, resulting in a reduction of costs. Additionally, there were reductions in sales personnel and related reductions in payroll-related expenditures, including commissions and travel. General and administrative expenses for the three months ended June 30, 2024, decreased by $300,000 to approximately $2.1 million compared to $2.4 million for the same period in 2023. General and administrative expenses for the six months ended June 30, 2024, decreased by $2.7 million to approximately $4 million compared to $6.7 million in the same period in 2023. The decrease for both three and six months of 2024 is due to a reduction in payroll-related expenditures, a decline in staffing levels and a reduction in rent expense as the company moved its headquarters at the end of the second quarter of 2023 to a smaller facility to reduce costs and professional fees. Research and development expenses for the three months ended June 30, 2024, decreased by $200,000 to $400,000 compared to $600,000 for the same period in the prior year. Research and development expenses for the six months ended June 30, 2024, decreased by $200,000 to $900,000 compared to approximately $1 million for the same period in the prior year. The primary reason for the decrease is due to a reduction in consulting and clinical trials as the company has paused clinical trial work to preserve cash. Non-GAAP adjusted EBITDA loss was $1.9 million for the three months ended June 30, 2024, compared to a loss of $3.7 million in the same period last year. For the six months ended June 30, 2024, the adjusted EBITDA loss was $4.1 million as compared to $9.1 million in the same period last year. Both reductions are primarily due to our continued efforts to reduce overall costs. We ended the quarter with net working capital of approximately $2.9 million, primarily due to cash and cash equivalents, including restricted cash totaling $1.2 million, and we remain debt free on our balance sheet. With that, I will now turn the call back over to Paul.
Paul Hickey: Thanks, Tom. At this time, I'm excited to have the opportunity to introduce Krishna Gupta, who will be the Chairman of the combined company post-merger to outline Vyome strategy and vision for the future. Krishna?
Krishna Gupta: Thanks, Paul, and I'm really excited to be here to speak with the shareholders of this great company. I appreciate the opportunity to talk about the exciting work we're doing in Vyome Therapeutics. We're a clinical-stage company focused on treating immuno-inflammatory diseases of unmet needs with next-generation solutions. Upon closing of this merger agreement, we will rename the company Vyome Holdings, Inc. to reflect our approach to building multiple accretive assets under the Vyome umbrella. The former ReShape stock will continue to be listed on the NASDAQ market under the new ticker symbol HIND, an ancient name for India, which is an integral part of Vyome's identity and competitive advantage. The Vyome team is a great balance of scientific prowess, big-picture vision, execution, experience and capital markets agility. I want to call attention to our scientific founder, Shiladitya Sengupta, a top student at India's best Medical School, an alumni of Cambridge and MIT. He's been a researcher at MIT and Harvard for years and has been a friend of mine for over a decade. We're a clinical stage company, laser-focused on identifying unmet medical needs and addressing them with novel approaches and smart clinical trial designs. We've very thoughtfully been building in the immuno-inflammation sector, which is a hot and expanding area, and we have a very promising pipeline developed over the past few years with potential, near-term catalysts treating rare and unmet diseases. If we zoom out, our current assets reflect some of our key competitive advantages. We're accessing world-class talent and world-class research at much lower cost, thanks to our proprietary connections to India, all in order to solve tangible, real-world problems with large U.S. market opportunities. This is an extremely timely generational opportunity. India is the biggest growth story in the world, especially as China's growth declined. We all know about the success of the Indian IT sector and the numerous successful Indian software founders and executives both in the U.S. and India. This theme is becoming increasingly tangible with healthcare as well. I'm very bullish on our ability to bring in additional opportunities, partnerships and acquisitions under the Vyome Holdings umbrella, deals that enable our future shareholders to access the special and growing innovation connection between the U.S. and India. From the onset, Vyome will be well positioned for success in the public markets, having proactively insured, have no debt, a clean capital structure and a very aligned board. As part of the execution of the merger agreement, we have commitments for additional capital, anchored in part by Dr. Ranjan Pai, Chairman of the Manipal Education and Medical Group and investors affiliated with Remus Capital and Iron Pillar. Certain of Vyome's current stockholders have committed to a minimum $7.3 million private placement in the combined company and its subsidiaries, which may be upsized through additional investments to close concurrently with the merger. Based on our anticipated cash flow projections, we should have adequate liquidity on hand to self-fund into the second half of '25. We plan to deploy the capital raised through the private placement to unlock significant value in our pipeline of immuno-inflammatory assets. Let me reiterate, we strongly believe that India is the world's greatest growth story, and we also believe that immuno-inflammation offers a significant opportunities for value creation. As such, we are excited about using our new public platform to strengthen our existing assets and unlock key value milestones from our pipeline, leveraging the world-class Indian innovation corridor and the U.S. market. We are confident in our ability to potentially build significant value with our pipeline of novel, local agent drugs for significant unmet needs, supported by a robust patent portfolio, effective drug development strategies, a balance sheet with no debt and prudent capital deployment, all with a focus on accreting value for shareholders. So in closing, we feel like we are very aligned with ReShape's shareholder expectations for a disciplined and focused business model executed flawlessly to help ensure we maximize shareholder value. Thank you in advance for your support and vote for this merger agreement. I'm excited to call all of you our shareholders. We look forward to providing you with updates on Vyome Holdings in the future, and I want to wish India a happy Independence Day. With that, I would like to turn the call back to Paul.
Paul Hickey: Thanks, Krishna. We are generally enthusiastic about the benefits we are poised to deliver to our shareholders as a result of the merger and asset purchase agreement, which will be described in more detail in an S-4 registration statement. That will include the proxy statement related to the merger and asset purchase agreement, followed by a holding of a shareholder meeting for the approval of the transactions. I'd also like to reiterate that our Board of Directors unanimously recommended the merger with Vyome along with the concurrent asset sale to Biorad. I'd like to express my gratitude again to Krishna for joining the call today to discuss the exciting prospects for Vyome Therapeutics. And as always, I want to thank our employees [technical difficulty]
Operator: Thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.
Q -:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.